Clinical Trial Results:
            A multicentre, randomised, placebo-controlled, double-blind, 4-arm parallel-group, 2-week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of GW642444H (100 and 400mcg administered once-daily in the morning via DISKUS™ dry-powder inhaler) compared with salmeterol (50mcg administered twice-daily via DISKUS dry-powder inhaler) and placebo in subjects with moderate COPD. 
    
| 
                 Summary 
         | 
        |
    EudraCT number  | 
        2006-004033-15 | 
    Trial protocol  | 
        NL | 
    Global completion date  | 
        
                                    10 May 2007
                             
         | 
    
| 
                 Paediatric regulatory details 
         | 
        |
    Is the trial part of an agreed EMA paediatric investigation plan?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 45 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 46 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
| 
                 Results information 
         | 
        |
    Results version number  | 
        v1(current) | 
    This version publication date  | 
        
                                    02 Jul 2016
                             
         | 
    
    First version publication date  | 
        
                                    02 Jul 2016
                             
         | 
    
    Other versions  | 
        |
    Summary report(s)  | 
                                108562-Clinical-Study-Result-Summary | 
    
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.